<p><em>經驗豐富的腫瘤學和生命科學高管將領導財務戰略並支持下一階段的增長</em></p>
<p>要查看此發佈的 PDF，請點擊這裏</p>
<p>, /PRNewswire/ -- Delphi Diagnostics 今天宣佈任命 Eric Lindquist 為首席財務官，任職於 2026 年 4 月 1 日生效。Lindquist 先生在製藥和診斷公司擁有數十年的領導經驗，在商業化、企業戰略和資本形成方面有着良好的業績記錄。他在公司推進內分泌活性指數®（EAI™）測試以改善乳腺癌治療決策的關鍵時刻加入 Delphi。</p>
<p>最近，Lindquist 先生擔任 InnoSIGN 的首席執行官，領導了公司的戰略轉型並完成了多輪融資。在加入 InnoSIGN 之前，他是 Celcuity 的首席商務和商業官，負責收購 gedatolisib，並幫助將該項目推進至 III 期乳腺癌臨牀試驗。</p>
<p>在職業生涯早期，Lindquist 先生在 Natera 擔任高級領導職務，發揮了關鍵作用，推出了 Signatera，這是一種針對每位患者獨特癌症特徵的個性化分子殘留病檢測。他還通過業務發展和戰略合作伙伴關係的角色，幫助羅氏確立了在伴隨診斷領域的領導地位。</p>
<p>“Eric 在腫瘤學、診斷和戰略金融交匯處擁有深厚的專業知識，” Delphi Diagnostics 首席執行官 Winz Casagrande 説。“他在引導公司通過關鍵增長里程碑方面的經驗，將對我們擴大 EAI 的可及性並繼續構建下一代乳腺癌診斷以指導個性化治療至關重要。”</p>
<p>“Delphi Diagnostics 在改變乳腺癌治療決策方面具有獨特的優勢，” Lindquist 先生説。“公司基於生物學的 EAI 方法有潛力為複雜的臨牀決策帶來更大的清晰度。我期待與團隊合作，執行其戰略並推動長期價值。”</p>
<p>Lindquist 先生獲得明尼蘇達大學的遺傳學和細胞生物學學士學位，以及 Capella 大學的 MBA 學位。</p>
<p><strong>關於 EAI</strong> Delphi Diagnostics 的內分泌活性指數®（EAI™）測試可以為 II-III 期 HR+ HER2- 乳腺癌的預後和預測劑量強度紫杉烷化療的益處提供可操作的信息。EAI 測量乳腺腫瘤的內分泌活性，作為預後使用時，指數分數根據分子亞型基因（RNA4）和腫瘤大小及區域淋巴結受累等臨牀因素進行基線預後調整。EAI 測試在多項研究中已被證明是 II-III 期乳腺癌患者長期結果的一致預後指標，獨立於其他預後測試，並且能夠預測對劑量密集化療的反應。</p>
<p><strong>關於 Delphi Diagnostics</strong> Delphi Diagnostics Inc. 是一家總部位於德克薩斯州的公司，專注於推進臨牀有效的乳腺癌治療預後和預測測試。Delphi Diagnostics, Inc. 擁有來自德克薩斯大學 MD 安德森癌症中心的獨家許可，以商業化內分泌活性指數，這項技術由 W. Fraser Symmans 博士的實驗室開發。內分泌活性指數（EAI）測試測量 II-III 期 HR+HER2- 乳腺癌的內分泌活性。Delphi 的願景是使 EAI 測試可供乳腺癌患者使用，併為個性化乳腺癌治療開闢新途徑。要了解更多信息，請訪問 www.delphi-diagnostics.com。</p>
<p>**Symmans 博士與 Delphi 有個人財務關係，這已被確定為與本研究的利益衝突，並由 MD Anderson 的利益衝突委員會進行管理。</p>
<p><strong>媒體聯繫人：</strong></p>
<p>Emily Granger</p>
<p>Delphi Diagnostics Inc.</p>
<p>[email protected]</p>
<p>508.341.9331</p>
<p>來源：Delphi Diagnostics Inc</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9REE2MzU5OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkxNzA1UFJfTkVXU19VU1BSX19fX19EQTYzNTk4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9REE2MzU5OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkxNzA1UFJfTkVXU19VU1BSX19fX19EQTYzNTk4"/></p>

CELC

美國醫藥設備 ETF - iShares

醫療業 ETF - Vanguard

標普生物技術 3 倍做多 - Direxion

醫藥突破 ETF - ALPS

動態生物技術與基因組 ETF - Invesco

標普生物技術 3 倍做空 - Direxion

2 倍做多納斯達克生物技術 ETF - ProShares

<p>德爾菲診斷公司已任命埃裏克·林奎斯特（Eric Lindquist）為首席財務官，任職時間自 2026 年 4 月 1 日起生效。林奎斯特是一位經驗豐富的腫瘤學和生命科學高管，他將領導公司的財務戰略，以推動其乳腺癌治療的內分泌活性指數（Endocrine Activity Index®）測試的發展。他之前的職位包括 InnoSIGN 的首席執行官和 Celcuity 的首席商務官。林奎斯特的專業知識預計將推動增長並增強乳腺癌診斷中的個性化治療選擇</p>

<p><em>Experienced oncology and life sciences executive to lead financial strategy and support the next phase of growth</em></p>
<div class="lb-trans"><p><em>經驗豐富的腫瘤學和生命科學高管將領導財務戰略並支持下一階段的增長</em></p>
</div><p>For a PDF of this release, please click here</p>
<div class="lb-trans"><p>要查看此發佈的 PDF，請點擊這裏</p>
</div><p>, /PRNewswire/ -- Delphi Diagnostics today announced the appointment of Eric Lindquist as Chief Financial Officer, effective April 1, 2026. Mr. Lindquist brings decades of leadership experience across pharmaceutical and diagnostics companies, with a strong track record in commercialization, corporate strategy, and capital formation. He joins Delphi at a pivotal time as the company advances its Endocrine Activity Index® (EAI™) test to improve treatment decision-making in breast cancer.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Delphi Diagnostics 今天宣佈任命 Eric Lindquist 為首席財務官，任職於 2026 年 4 月 1 日生效。Lindquist 先生在製藥和診斷公司擁有數十年的領導經驗，在商業化、企業戰略和資本形成方面有着良好的業績記錄。他在公司推進內分泌活性指數®（EAI™）測試以改善乳腺癌治療決策的關鍵時刻加入 Delphi。</p>
</div><p>Most recently, Mr. Lindquist served as Chief Executive Officer of InnoSIGN, where he led a strategic transformation of the business and completed multiple financing rounds. Prior to InnoSIGN, he was Chief Business and Commercial Officer at Celcuity, where he led the acquisition of gedatolisib and helped advance the program into Phase III breast cancer trials.</p>
<div class="lb-trans"><p>最近，Lindquist 先生擔任 InnoSIGN 的首席執行官，領導了公司的戰略轉型並完成了多輪融資。在加入 InnoSIGN 之前，他是 Celcuity 的首席商務和商業官，負責收購 gedatolisib，並幫助將該項目推進至 III 期乳腺癌臨牀試驗。</p>
</div><p>Earlier in his career, Mr. Lindquist held senior leadership roles at Natera, where he played a key role in launching Signatera, a personalized molecular residual disease test tailored to each patient's unique cancer signature. He also contributed to establishing Roche as a leader in companion diagnostics through roles in business development and strategic partnerships.</p>
<div class="lb-trans"><p>在職業生涯早期，Lindquist 先生在 Natera 擔任高級領導職務，發揮了關鍵作用，推出了 Signatera，這是一種針對每位患者獨特癌症特徵的個性化分子殘留病檢測。他還通過業務發展和戰略合作伙伴關係的角色，幫助羅氏確立了在伴隨診斷領域的領導地位。</p>
</div><p>&#34;Eric brings deep expertise at the intersection of oncology, diagnostics, and strategic finance,&#34; said Winz Casagrande, Chief Executive Officer of Delphi Diagnostics. &#34;His experience leading companies through critical growth milestones will be instrumental as we expand access to EAI and continue to build next-generation breast cancer diagnostics to guide personalized treatment.&#34;</p>
<div class="lb-trans"><p>“Eric 在腫瘤學、診斷和戰略金融交匯處擁有深厚的專業知識，” Delphi Diagnostics 首席執行官 Winz Casagrande 説。“他在引導公司通過關鍵增長里程碑方面的經驗，將對我們擴大 EAI 的可及性並繼續構建下一代乳腺癌診斷以指導個性化治療至關重要。”</p>
</div><p>&#34;Delphi Diagnostics is uniquely positioned to transform how treatment decisions are made in breast cancer,&#34; said Mr. Lindquist. &#34;The company's biology-driven approach with EAI has the potential to bring greater clarity to complex clinical decisions. I look forward to working with the team to execute on its strategy and drive long-term value.&#34;</p>
<div class="lb-trans"><p>“Delphi Diagnostics 在改變乳腺癌治療決策方面具有獨特的優勢，” Lindquist 先生説。“公司基於生物學的 EAI 方法有潛力為複雜的臨牀決策帶來更大的清晰度。我期待與團隊合作，執行其戰略並推動長期價值。”</p>
</div><p>Mr. Lindquist earned a Bachelor of Science in genetics and cell biology from the University of Minnesota and an MBA from Capella University.</p>
<div class="lb-trans"><p>Lindquist 先生獲得明尼蘇達大學的遺傳學和細胞生物學學士學位，以及 Capella 大學的 MBA 學位。</p>
</div><p><strong>About EAI</strong> Delphi Diagnostics' Endocrine Activity Index® (EAI™) test can provide actionable information for prognosis and prediction of dose-intense taxane-based chemotherapy benefit in stage II-III, HR+ HER2- breast cancer. The EAI measures endocrine activity in a breast tumor, and for prognostic use, the Index Score is adjusted for baseline prognosis using molecular subtype genes (RNA4) and clinical factors such as tumor size and regional lymph node involvement. The EAI test has been shown in various studies to be a consistent prognostic indicator for long-term outcomes in stage II-III breast cancer patients, to be independent of other prognostic tests, as well as to be predictive for response to dose-dense chemotherapy.</p>
<div class="lb-trans"><p><strong>關於 EAI</strong> Delphi Diagnostics 的內分泌活性指數®（EAI™）測試可以為 II-III 期 HR+ HER2- 乳腺癌的預後和預測劑量強度紫杉烷化療的益處提供可操作的信息。EAI 測量乳腺腫瘤的內分泌活性，作為預後使用時，指數分數根據分子亞型基因（RNA4）和腫瘤大小及區域淋巴結受累等臨牀因素進行基線預後調整。EAI 測試在多項研究中已被證明是 II-III 期乳腺癌患者長期結果的一致預後指標，獨立於其他預後測試，並且能夠預測對劑量密集化療的反應。</p>
</div><p><strong>About Delphi Diagnostics</strong> Delphi Diagnostics Inc. is a Texas-based company focused on advancing clinically valid tests for the prognosis and prediction of breast cancer treatment. Delphi Diagnostics, Inc. holds an exclusive license from The University of Texas MD Anderson Cancer Center in Houston, TX to commercialize the Endocrine Activity Index, a technology that was developed by the laboratory of Dr. W. Fraser Symmans**. The Endocrine Activity Index (EAI) test measures endocrine activity in stage II-III, HR+HER2- breast cancer. Delphi's vision is to make the EAI test available to breast cancer patients and open new pathways for personalized breast cancer treatment. To learn more, visit www.delphi-diagnostics.com.</p>
<div class="lb-trans"><p><strong>關於 Delphi Diagnostics</strong> Delphi Diagnostics Inc. 是一家總部位於德克薩斯州的公司，專注於推進臨牀有效的乳腺癌治療預後和預測測試。Delphi Diagnostics, Inc. 擁有來自德克薩斯大學 MD 安德森癌症中心的獨家許可，以商業化內分泌活性指數，這項技術由 W. Fraser Symmans 博士的實驗室開發。內分泌活性指數（EAI）測試測量 II-III 期 HR+HER2- 乳腺癌的內分泌活性。Delphi 的願景是使 EAI 測試可供乳腺癌患者使用，併為個性化乳腺癌治療開闢新途徑。要了解更多信息，請訪問 www.delphi-diagnostics.com。</p>
</div><p>**Dr. Symmans has a personal financial relationship with Delphi that has been identified as a conflict of interest with this research and is managed by MD Anderson's Conflict of Interest Committee.</p>
<div class="lb-trans"><p>**Symmans 博士與 Delphi 有個人財務關係，這已被確定為與本研究的利益衝突，並由 MD Anderson 的利益衝突委員會進行管理。</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒體聯繫人：</strong></p>
</div><p>Emily Granger</p>
<div class="lb-trans"><p>Emily Granger</p>
</div><p>Delphi Diagnostics Inc.</p>
<div class="lb-trans"><p>Delphi Diagnostics Inc.</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>508.341.9331</p>
<div class="lb-trans"><p>508.341.9331</p>
</div><p>SOURCE Delphi Diagnostics Inc</p>
<div class="lb-trans"><p>來源：Delphi Diagnostics Inc</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9REE2MzU5OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkxNzA1UFJfTkVXU19VU1BSX19fX19EQTYzNTk4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DA63598&amp;Transmission_Id=202605191705PR_NEWS_USPR_____DA63598&amp;DateId=20260519"/></p>

Delphi Diagnostics 公司任命 Eric Lindquist 為首席財務官